Final-Program-ATS-2023-AP.vp

TUESDAY • MAY 23

239

P662 Programmed Cell Death Protein-1 Receptor Modulates Chemokine Ligand-18 Secretion in Macrophages: An Important Checkpoint Inhibitor Pneumonitis Chemokine/ M.I. Ghanbar, Baltimore, MD P663 Role of Hemoxygenase-1 as a Central Mediator of Acute Radiation Pneumonitis Revealed in a Human Lung Alveolus-on-a-Chip/ Q. Dasgupta, Boston, MA P664 Establishing a Diagnosis and the Prevalence of Eosinophilic Granulomatosis With Polyangiitis Through Claims Data Using Machine Learning/ P.A. Merkel, Philadelphia, PA P665 Machine Learning Prediction of Severe Asthma and COPD Hospital Readmission/ H. Li, New Haven, CT P666 Development and Validation of Deep Learning Models for Diagnosing Bronchial Asthma Using Methacholine Provocation Test, Induced Sputum Analysis and Exhaled Nitric Oxide Measurement/ N. Kang, Seoul, Korea, Republic of

P645 Exposure-Efficacy Analysis Supports Proof of Concept for Efzofitimod in Pulmonary Sarcoidosis/ R. Adams, San Diego, CA P646 Diagnosing Sarcoidosis Associated Small Fiber Neuropathy/ L.R.M. Raasing, Nieuwegein, Netherlands P647 Targeting Signal Regulatory Proteins (SIRPs) to Suppress Sarcoidosis Granuloma Responses/ E.D. Crouser, Columbus, OH P648 Renin-angiotensin-aldosterone System Plays an Integral Role During Sarcoidosis Granuloma Formation/ E.D. Crouser, Columbus, OH P649 High MTOR Activity in Bronchoalveolar Lavage Cells From Patients With Sarcoidosis/ A. Prasse, Hannover, Germany P650 Residential Bioaerosol Concentrations and Serum Inflammatory Markers in Pulmonary Sarcoidosis/ E.M. Stapleton, Iowa City, IA P651 The Role of Airway Epithelial Responses in Sarcoidosis/ M. Hagner, Iowa City, IA P652 Relative Change in Plasma Anti-GM-CSF Antibody Levels May Correlate With Clinical Improvement in Autoimmune Pulmonary Alveolar Proteinosis/ E. Lee, Los Angeles, CA P653 The Use of Procalcitonin in the Diagnosis of Idiopathic Acute Eosinophilic Pneumonia/ A. Elkhapery, Rochester, NY P654 Experimental Models of Cough Hypersensitivity in Guinea Pig Useful to Study Novel Mechanisms for the Treatment of Chronic Cough/ C. Martucci, Parma, Italy P655 Clinical Characteristics of Patients With Systemic Sclerosis and Early Pulmonary Involvement/ I. Acosta Sanchez, Chicago, IL P656 Potential Biomarkers for the Diagnosis of Patients With Lung Fibrosis/ M.-J. Cruz, Barcelona, Spain P657 A Phase I Study (Safety, Tolerability, and Pharmacokinetic Study) of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis/ H. Doi, Tokyo, Japan P658 Multimodality Approach to Characterizing the Distinctive Hallmarks of Lung Fibrosis: A Mouse Model With Bleomycin and Indocyanine Green/ A. Grandi, Parma, Italy P659 Suppression of Lung Nitrogen Mustard-induced Pulmonary Fibrosis, Oxidative Stress and Inflammatory Macrophage Activation by the Farnesoid X Receptor Agonist, Obeticholic Acid/ J. Meshanni, Piscataway, NJ P660 The Prevalence of IPF and Progressive Pulmonary Fibrosis in South Africa/ G.K. Soin, Cape Town, South Africa P661 Respiratory Status After Hematopoietic Stem Cell Transplantation for Primary Imunodeficiency/ H. Salvator, Suresnes, France

BEHAVIORAL • CLINICAL THEMATIC POSTER SESSION

C35

HEALTH SERVICES AND EPIDEMIOLOGY RESEARCH IN HOSPITALIZED AND CRITICALLY ILL POPULATIONS

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P851 To Consult Critical Care or Not: Evaluating Hospitalist Perceptions of Critical Care Consultations in the Intermediate Care Unit/ M. Dunlop, Boston, MA P852 Utilizing a User-centered Design Approach in the Development of an Intensive Care Unit Triage Intervention for Patients Presenting to the Emergency Department With Acute Respiratory Failure/ K.C. Vranas, Portland, OR P853 Characteristics of Rural Intensive Care Units in the United States Prior to the COVID-19 Pandemic/ Y. Engeda, Ann Arbor, MI P854 Cost-sharing for Intensive Care Unit Admissions/ S. Kannan, Boston, MA P855 Symptom Cluster Characterization Upon Inpatient

Admission in Those With Independent or Comorbid Heart Failure and Chronic Obstructive Pulmonary Disease/ A. Bugajski, Lakeland, FL

ATS 2023 • Washington, DC